Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Washington
With
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The main study be a two arm 10-month, cross-over randomized controlled trial of 200 participants treated with in-center hemodialysis in the Seattle and San Francisco area comparing a strategy of targeting home vs. pre-dialysis systolic blood pressure \<140 mmHg in reducing rates of intradialytic hypotension. The target systolic blood pressure of 100-140 mmHg will be achieved using an algorithm of volume management and anti-hypertensive medication adjustment every two weeks. Home blood pressure measures will be recorded throughout via a mobile health blood pressure monitor over the 10-month study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years or older
Undergoing in-center, thrice weekly hemodialysis for treatment of end stage renal disease (ESRD)
Greater than 3 months since initiation of dialysis
No anticipated change to peritoneal dialysis or kidney transplant within 10 months
Life expectancy greater than 10 months
Hypertension (defined as mean pre-dialysis SBP \> 140 mmHg over prior 2 weeks or taking BP medications)
Able to obtain/measure a brachial blood pressure at dialysis and at home (e.g., no left ventricular assist device, blood pressure not been taken routinely in lower extremity at dialysis unit)
No condition that the primary nephrologist or PIs feel precludes participation
You may not be if
Incarcerated or institutionalized (prohibits home blood pressure measurement)
Participating in another intervention study that may affect blood pressure
Pregnant or anticipated pregnancy or breastfeeding (as this will require increase to more than three times a week dialysis and/or preclude use of some classes of blood pressure medications)
